MEMehmet Erdogan

Mehmet Erdogan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehmet Erdogan has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • M. Karadeniz

    Department of Endocrinology and Metabolism Disease, Ege University Medical School, Izmir, Turkey

    8 shared publications
  • A. G. Ozgen

    Department of Endocrinology and Metabolism Disease, Ege University Medical School, Izmir, Turkey

    6 shared publications
  • A. Berdeli

    Laboratory of Molecular Medicine, Department of Pediatrics, Ege University Medical School, Izmir, Turkey

    5 shared publications
  • C. Yilmaz

    Department of Endocrinology and Metabolism Disease, Ege University Medical School, Izmir, Turkey

    5 shared publications
  • M. Tuzun

    4 shared publications
  • S. Cetinkalp

    Department of Endocrinology and Metabolism Disease, Ege University Medical School, Izmir, Turkey

    4 shared publications

Latest Publications

  • Effects of combination of metformin and pioglitazone on AMPK/mTOR signal pathway, p53 and apoptosis in human anaplastic thyroid cancer cells

    by Nilufer Ozdemir Kutbay, Mehmet Erdogan, Banu Sarer Yurekli, Cansu Caliskan Kurt, Cumhur Gunduz, Cigir Biray Avci

    Thyroid cancer is the most common malignant tumor of the human endocrine system. Recently, its incidence has increased significantly. Anaplastic cancer constitutes 2–4% of thyroid cancers and remains aggressive. The life expectancy is 2–6 months. It is often beyond the surgical margin. External radiation therapy or chemotherapy are the treatment options. Therefore, new therapeutic approaches are needed. Peroxisome proliferator-activated receptor (PPAR) gamma is a DNA-binding nuclear hormone receptor and regulates transcription effects in cell energy metabolism. PPAR gamma agonists may inhibit tumor growth through terminal cell differentiation induction, cell cycle arrest, apoptosis induction and angiogenesis inhibition. PPAR gamma agonists show significant antitumor activities against various cancers both in vitro and in vivo. Metformin (1,1-Dimethylbiguanide) is the most widely used drug in treatment of type 2 diabetes patients. Preclinical data show its anticancer effects. The molecular mechanisms of metformin in cancer cells is still unknown. In our study, we plan to evaluate effects of combination of metformin and pioglitazone on AMPK/mTOR signal pathway, p53 and apoptosis in human anaplastic thyroid cancer cells. In C643 and SW1736 cell lines, IC50 doses of metformin and pioglitazone were found as 17.69 and 11.64 mM, and 27.12 and 23.17 μM respectively. The combination of metformin and pioglitazone was determined as additive with isobologram analyses. Both of the compounds induce apoptosis separate or in combination. Consequently, we have evaluated the down regulation of the expression levels of oncogenic AKT3, CHUK, CDC42, EIF4E, HIF1A, IKBKB, ILK, PIK3CA, PIK3CG, PLD1, PRKCA, RICTOR genes in MET and PIO combination treated cells. Moreover, expression levels of tumor suppressor DDIT4, DDIT4L, EIF4EBP1, EIF4EBP2, FKBP1A, FKBP8, GSK3B, MTOR, MYO1C, PTEN, ULK1, ULK2 genes were found to increase functionality. The results show that these agents can be used in the treatment of thyroid cancer as novel therapeutic agents.


  • Efficacy of zoledronic acid treatment in Paget disease of bone

    by Emine Kartal Baykan, L Fusun Saygili, Mehmet Erdogan, A Gokhan Ozgen, Sevki Cetinkalp, Candeger Yilmaz

    Purpose: Paget disease is a disease of bone of unknown etiology with increased bone turnover that results in defective bone microarchitecture and bone deformity. Bisphosphonates are used in symptomatic Paget disease of bone. Clinical trials have shown that zoledronic acid was more effective than other bisphosphonates in treatment of Paget disease. Methods: In this study, we retrospectively reviewed the remission and relapse statuses of 12 patients with Paget disease of bone, who were seen as outpatients between October 2011 and October 2013. We evaluated alkaline phosphates, osteocalcin, deoxypyridinoline levels measured before and at 6th, 12th, 18th months of treatment (Table 1). Results: Pretreatment and post-treatment valus for alkaline phosphates, deoxypyridinoline, osteocalcin were as follows; 473±256 U/l, 14.99±7.63 mmol/l, 21.09±3.18 ng/ml and 82±13 U/l, 5.14±1.11 mmol/l, 8.57±4.31 ng/ml. Remission was achieved in all patients after treatment. The levels indicated remission continued at 12th and 18th months of treatment. There was statistically significant difference between pretreatment and post-treatment values. No statistically significant difference between the levels measured at 6th, 12th and 18th months of treatment were detected. Table 1 Pretreatment and posttreatment results Basal (n:12) 6th month (n:12) 12th month (n:12) 18th month (n:12) ALP (40–129 U/l) 473±256 82±13* 67±15 *,† 74±12.5*,†, ‡ DPD (2.3–5.4 mmol/l) 14.99±7.63 5.14±1.11* 4.90±1.18,† 5.09±1.31*,†, ‡ OC (2–15 ng/ml) 21.09±3.18 8.57±4.31* 4.34±1.82*,† 5.45±1.35*,†, ‡ *P0.05; difference between values of 6th, 12th, and 18th months were not statistically significant. Conclusion: We recommend zoledronic acid in the first line treatment of Paget disease of bone in achieving and maintaining remission. Keywords: zoledronic acid, bisphosphonates, bone turnover, Paget disease

  • Atorvastatin medullar thyroid cancer over TT cell line impact of apoptosis and calcitonin over gene expression

    by Emine Kartal Baykan, Cigir Biray Avci, Mehmet Erdogan, Sevki Cetinkalp, A Gokhan Ozgen, Cumhur Gunduz, L Fusun Saygili

    Medullar thyroid cancer (MTK) approximately constitutes 5% of thyroid cancer, over the 25% cases it progresses in familial form. In charge of genetic inherited clinical features in RET protooncogene ‘germ-line’ makes up activating mutations. In post RET mutation in association with tyrosine kinase activation oncogenic cell proliferation is increased. In medullary thyroid cancer persistent and recurrence disease management is complicated, because it is unresponsive toward chemotherapy, radiotherapy, and radioactive iodine therapy. In these cases, RET and tyrosine are termed as the agents targeting kinase receptor activity. Tyrosine kinas inhibitors may be potential to stabilize metastatic disease, but in terms of survival time period they do not lead to any variation and due to widespread of side effects their clinical administration remains difficult. Stains inhibiting mevolanat channel by HMG Co A reductase inhibition, based on proapoptotic, antiangiogenetic, and immunomodulatuar effect were identified to be able to cancer cell growth in previous plenty of studies. In the present study, throughout TT cell line we investigated atorvastatin’s apoptotic impact in cancer cells and calcitonin’s variation gene expression. TT cell’s administered in atorvastatin varying doses (12.5–25–50–60–70–80–90–100–125–150–200 μM) and at 24. Hours IC 50 ratio accounted 90 μM, 48. Time IC 50 value 80 μM and at 72. Hours IC 50 value calculated as 80 μM. Atorvastatin’s apoptotic effect; evaluated in correlation with caspase 9 activity. In comparison with atorvastatin’s control cohort at 24. Hours 1.273-fold, at 48. Hours 1.660-fold and at 72 h 1.716-fold caspase 9 activity found to proliferate. In post atorvastatin calcitonin gene expression, compare to control cohort at 24. Hours identified to attenuate 1.377-fold, at 48. Hours identified to attenuate 7.290-fold and at 72. Hours identified to attenuate 8.494-fold. Eventually; atorvastatin along the TT cell line as dependent on dose and time increase apoptosis and calcitonin alleviate gene expression. Owing to atorvastatin easy clinical use and lesser side effects in the therapy of progressed MTK cases it may be deemed as a promising new agent.

  • Interleukin-10 (-1082G/A) Gene Polymorphism in Patients With Type 2 Diabetes With and Without Nephropathy

    by Mehmet Erdogan, Sevki Cetinkalp, Ahmet Gokhan Ozgen, Fusun Saygili, Afig Berdeli, Candeger Yilmaz

    Objective: Interleukin (IL)-10 is a major anti-inflammatory cytokine that plays a crucial role in the regulation of the immune system. IL-10 has met the criteria for an anti-inflammatory and an immunosuppressive cytokine, its activity may be important for clinical outcome of diabetic nephropathy (DN). We aimed at evaluating the relation between the genotypic and allelic frequencies of the IL-10 (-1082G/A) polymorphisms, and their association with the risk to develop DN in the Turkish population. Research Design and Methods: The (IL)-10 (-1082G/A) genotypes were retrospectively determined in 43 patients with nephropathy and 48 without nephropathy and a control group of 112 healthy individuals. The polymorphisms were analyzed by polymerase chain reaction restriction fragment length polymorphism. Results: This genotype distribution was different between control subjects and patients with type 2 diabetes in which 24.2% were AA, 75.8% were GA, and 0% were GG (p0.05). The genotype frequencies were AA, 27.9%; GA, 72.1%; and GG, 0% in patients with diabetes with nephropathy versus AA, 20.8%; GA, 79.2%; and GG, 0% in those without nephropathy (p>0.05). Conclusions: The polymorphisms of IL-10 (-1082G/A) genes were significantly associated with the occurrence of patients with type 2 diabetes. The IL-10 (-1082G/A) genotype and allele frequencies were not different between patients with diabetes with nephropathy and those without nephropathy. Therefore, we conclude that the IL-10 (-1082G/A) gene polymorphism is not associated with the development of DN in Turkish patients with type 2 diabetes.


  • Open Access

    Characteristics of anemia in subclinical and overt hypothyroid patients

    by Erdogan Mehmet, Kosenli Aybike, Sencer Ganidagli, Kulaksizoglu Mustafa

    Thyroid hormones stimulate directly or indirectly growth of erythroid colonies through erythropoietin. Anemia is often the first sign of hypothyroidism. Hypothyroidism can cause a wide variety of anemic disorders. Numerous mechanisms are involved in the pathogenesis of these anemias that can be microcytic, macrocytic and normocytic. We designed this study to investigate the anemia frequency and if present, etiology of anemia in hypothyroid patients. 100 patients with overt hypothyroid, 100 patients with subclinical hypothyroid, and 200 healthy controls were enrolled in this study. Overt hypothyroidism diagnosis is done when elevated TSH and low levels of free T4 and/or free T3 have been observed. Subclinical hypothyroidism is defined as elevated serum TSH with normal free T(4) and free T(3) levels. Peripheral smears of the anemic patients were examined. Anemia prevalence was 43% in the overt hypothyroid group, 39% in the subclinical hypothyroid group, and 26% in the control group (p=0.0003 and p=0.021 respectively related to controls). Thus, the frequency of anemia in subclinical hypothyroidism is as high as that in overt hypothyroidism. There was no difference between the hypothyroid groups in terms of anemia. Vitamin B12, Fe, and folic acid were similar between these groups. According to our findings, anemia of chronic disease is the most common type of anemia in hypothyroid patients. Suspicion of hypothyroidism should be considered in anemias with uncertain etiology.


  • Metabolic syndrome prevalence in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters

    by M Erdogan, A Canataroglu, S Ganidagli, M Kulaksızoglu

    One of the common features of hypothyroidism is weight gain or failure to lose weight. Bradycardia and mild hypertension can be seen as well. Impact of thyroid hormone deficiency on glucose and insulin metabolism is not fully understood. Thyroid hormones play a role in lipid synthesis, metabolism and mobilization. Metabolic syndrome is a status where most features of hypothyroidism can be seen. Our aim is to investigate the frequency of metabolic syndrome in hypothyroid patients. One hundred overt hypothyroid patients, 100 subclinical hypothyroid patients and 200 healthy controls enroled in this study. The Third Adult Treatment Panel of the National Cholesterol Education Program (NCEP-ATP III) criteria were used for metabolic syndrome diagnosis. Body mass index was similar among the groups. Waist circumference was lower in the control group than in the hypothyroid patients (p=0.0001). Homeostasis model assessment (HOMA) insulin resistance was higher in the hypothyroid group than in the control (p=0.008) and subclinical hypothyroid (p=0.014) groups. Metabolic syndrome prevalence was 44% in the hypothyroid group, 35% in the subclinical hypothyroid group and 33% in the control group (p=0.016 for the hypothyroid group vs controls and p=0.002 for the hypothyroid group vs subclinical hypothyroid group). Waist circumference was larger in the hypothyroid metabolic syndrome patients than in the subclinical hypothyroid group and controls (p=0.001). Blood glucose, lipid parameters and blood pressure were similar among the groups. Metabolic syndrome is increased in patients with hypothyroidism, therefore hypothyroidism should be considered in newly diagnosed metabolic syndrome patients.


  • Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers

    by M. Erdogan, S. Solmaz, A. Canataroglu, M. Kulaksızoglu, S. Cetinkalp, A. G. Ozgen, F. Saygili, C. Yilmaz

    Plasma TAFI may participate in arterial thrombosis in cardiovascular diseases (CVD) and may be involved in the mechanism of vascular endothelial damage in diabetic patients. The aim of this study was to investigate the association of plasma TAFI antigen level in the development of diabetic foot ulcer in Type 2 diabetes. The TAFI antigen levels were determined in 50 patients with diabetic foot ulcers and 34 patients without diabetic foot ulcers and 25 healthy individuals. We measured TAFIa/ai antigen in plasma samples with a commercially available ELISA Kit. Diabetic foot ulcer group and diabetic group were similar in terms of mean age and sex distribution. Diabetes duration, retinopathy, neuropathy, macrovascular disease and infection were related to diabetic foot ulcers. HbA1c, HDL-cholesterol and Folic Acid levels were decreased in the diabetic foot ulcer group. TAFI levels were 99.44 ± 55.94% in control group, 135.21 ± 61.05% in diabetic foot ulcer group, 136.75 ± 59.38% in diabetic group and was statistically different (P < 0.05). But no difference was seen in TAFI levels between the diabetic foot ulcer group and diabetic group (P > 0.05). No significant difference in plasma TAFI levels were seen between diabetic foot ulcer stages. TAFI antigen levels are increased in Type 2 diabetic patients, but are not related to diabetic foot ulcer development.


  • Demographic, clinical, laboratory, ultrasonographic, and cytological features of patients with Hashimoto’s thyroiditis: results of a university hospital of 769 patients in Turkey

    by Mehmet Erdogan, Nihat Erdem, Sevki Cetinkalp, Ahmet Gokhan Ozgen, Fusun Saygılı, Candeger Yilmaz, Mehmet Tuzun, Taylan Kabalak

    We investigated the demographic and clinical features of patients with Hashimoto’s thyroiditis who had been diagnosed and treated in Ege University, the main referral center in the Aegean region of Turkey. Medical records of patients who had been followed in the endocrinology clinic of Ege University were retrospectively evaluated. Patients who had been diagnosed as having any thyroid disorder were determined. Patients with Hashimoto’s thyroiditis were selected among those patients. Seven hundred and sixty-nine patients fulfilled diagnostic criteria for Hashimoto’s thyroiditis (725 females, 44 males; mean age 41.76 ± 12.49 years). 62.7% of patients were between 30 and 50 years of age. 53.3% of females and 63.6% of males had diffuse enlargement of the thyroid gland. TSH level was above 4.0 IU/l in 25.6% of females and 27.4% of males. Anti-tyroglobulin antibody was positive in 92% of females and 93.2 % of males. Anti-thyroid peroxidase antibody was positive in 98.4 % of females (713 patients) and 100% of males. Thyroid ultrasonography demonstrated single nodule in 52.2% and multiple nodules in 11.3% of female patients; and single nodule 32% and multiple nodules in 20% of male patients. Fine-needle aspirations of the nodules were performed in 207 patients, and none of those biopsies was diagnosed as malignant. Women with suspicious biopsis were operated. After surgery, we found that, 2% (n = 4) of patients with FNAC diagnosis of suspicious biopsies were papillary carcinoma and the other patients (3% (n = 6)) were lymphocytic thyroiditis. Age and sex distribution and laboratory findings of our patients were comparable to the previous reports. Nodule formation was the most common ultrasonographic finding in our patients, probably due to pseudonodularity. We found four women patients with thyroid cancer in our population.


  • The relationship of the interleukin‐6 −174 G>C gene polymorphism with cardiovascular risk factors in Turkish polycystic ovary syndrome patients

    by M. Erdogan, M. Karadeniz, A. Berdeli, S. Tamsel, C. Yilmaz

    We aimed to evaluate the relationship between 174 promoter region of the interleukin-6 (IL-6) C/G gene polymorphism and high sensitive C-reactive protein (hs-CRP), fibrinogen and carotis intima-media thickness (CIMT), body mass index, homeostatic model assessment (HOMA) insulin resistance index, serum lipid parameters, in polycystic ovary syndrome (PCOS) patients carrying a potential risk for developing cardiovascular disease (CVD). We studied 88 PCOS patients and 119 healthy controls. PCOS was defined by the Rotterdam PCOS consensus criteria. The genotype IL-6 distribution did differ between the control group (CC 10.1%, GC 63.0%, GG 29.6%) and the PCOS patients (CC 5.7%, GC 29.5%, GG 64.8%) (P < 0.001). The frequency of the polymorphic G allele was also no similar for the group with PCOS as for the control group with 79.5% and 58.4% respectively (P < 0.001). Both in PCOS patients and in control group, no statistically significant difference was determined between C/C, G/C and G/G, and blood cholesterol levels, triglyceride levels, high-density lipoprotein levels, low density lipoprotein levels, fasting blood sugar levels, insulin levels, HOMA values, CIMT measurements either on the right or left side, hs-CRP, f-testosterone, fibrinogen and 17 alpha-hydroxy-progesterone levels (P > 0.05). Gene polymorphism of IL-6 -174 G>C is a risk factor for PCOS in Turkish patients, but we found no relationship between the cardiovascular risk factors and IL-6 -174 G>C gene polymorphism in women with PCOS and healthy subjects. Our negative results in risk factors of CVD can probably be explained by the fact that metabolic parameters and endothelial systems of patients may not yet be affected in this short time of period.